Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma.

Antimicrobial Agents and Chemotherapy
H KönigR Kurth

Abstract

The reverse transcriptase from human immunodeficiency virus type 1 was purified from the virus to near homogeneity. The enzyme was shown to possess both RNA-dependent and DNA-dependent DNA-synthesizing activity. Activated DNA as a heteropolymeric substrate was used as efficiently as was the homopolymeric substrate poly(rA)-oligo(dT). The Michaelis-Menten constants were determined for each of the four nucleotides needed to elongate a natural template primer. Azidothymidine triphosphate, a well-known inhibitor of the enzyme, inhibited the enzyme competitively with respect to dTTP and noncompetitively with respect to the other nucleotides. Azidothymidine triphosphate acted as an efficient inhibitor of cellular DNA polymerase gamma, whereas other enzymes of eucaryotic DNA metabolism, namely, DNA polymerase alpha-primase and DNA polymerase beta, were not inhibited. This finding may explain why some acquired immunodeficiency syndrome patients suffer side effects during azidothymidine therapy.

References

May 1, 1986·Antimicrobial Agents and Chemotherapy·L Vrang, B Oberg
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P A FurmanH Mitsuya
Feb 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A HiziS H Hughes
Oct 1, 1985·Analytical Biochemistry·H HiranoT Iwamura
May 1, 1986·Nature·J CoffinP Vogt
Nov 1, 1984·Journal of Cellular Physiology·M A WaqarJ A Huberman
Nov 22, 1984·Biochimica Et Biophysica Acta·H D RiedelR Knippers
Jan 15, 1980·Biochemical and Biophysical Research Communications·M OguroM Yamada

❮ Previous
Next ❯

Citations

Jun 5, 2003·The Lancet Infectious Diseases·Anthony Emmanuel O OgedegbeAnna Mae Diehl
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·J EnnenR Kurth
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·M T DittmarR Kurth
Jun 29, 2010·International Journal of Pharmaceutics·Rubiana Mara MainardesMaria Palmira Daflon Gremião
Jun 8, 2006·Environmental and Molecular Mutagenesis·James J Kohler, William Lewis
Sep 27, 1996·Biochemical Pharmacology·G SailajaA Antony
Mar 27, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·C Loveday
Mar 8, 2019·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jennifer JaoUNKNOWN Pediatric HIV/AIDS Cohort Study
Mar 7, 2008·Microbiology and Molecular Biology Reviews : MMBR·Cécile VoissetDavid J Griffiths
Dec 18, 2002·American Journal of Physiology. Heart and Circulatory Physiology·William Lewis
Aug 3, 2005·The Biochemical Journal·Patrick C BradshawDavid C Samuels
Jun 15, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·W LewisB J Day
Jan 1, 2014·The Pediatric Infectious Disease Journal·Jennifer Jao, Elaine J Abrams
Mar 4, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·W LewisP Klotman
Apr 5, 2014·Acta Crystallographica. Section D, Biological Crystallography·Vladimir TimofeevInna Kuranova
Oct 1, 1991·Journal of Virology·D BinningerR Kurth

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.